Equities Analysts Issue Forecasts for NMRA Q1 Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Investment analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Neumora Therapeutics in a research report issued on Monday, March 3rd. William Blair analyst M. Minter expects that the company will earn ($0.44) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share. William Blair also issued estimates for Neumora Therapeutics’ Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.43) EPS and Q4 2026 earnings at ($0.45) EPS.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.09.

Several other analysts have also recently issued reports on NMRA. Royal Bank of Canada reiterated a “sector perform” rating and issued a $4.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday. Bank of America reduced their price target on Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Needham & Company LLC restated a “buy” rating and set a $5.00 target price on shares of Neumora Therapeutics in a research note on Tuesday. JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $18.00 to $15.00 in a research note on Tuesday, November 5th. Finally, HC Wainwright lowered their price target on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.50.

Neumora Therapeutics Stock Up 0.7 %

Shares of NMRA stock opened at $1.41 on Wednesday. The firm has a 50 day moving average of $3.02 and a two-hundred day moving average of $8.81. The stock has a market capitalization of $227.80 million, a PE ratio of -0.75 and a beta of 2.50. Neumora Therapeutics has a 52 week low of $1.35 and a 52 week high of $21.00.

Institutional Investors Weigh In On Neumora Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of NMRA. Mirae Asset Global Investments Co. Ltd. acquired a new position in Neumora Therapeutics during the fourth quarter worth approximately $61,000. PNC Financial Services Group Inc. purchased a new position in shares of Neumora Therapeutics during the fourth quarter worth approximately $64,000. Quantbot Technologies LP acquired a new position in shares of Neumora Therapeutics in the 4th quarter valued at $92,000. PEAK6 LLC purchased a new stake in Neumora Therapeutics in the 4th quarter valued at $117,000. Finally, EntryPoint Capital LLC acquired a new stake in Neumora Therapeutics during the 4th quarter worth $135,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.